PCSK9 and type 2 diabetes mellitus: Our findings indicate that subjects with higher WAT‐surface expression of LDLR and CD36, identified by lower plasma PCSK9, have an accumulation of WAT and systemic activation of NLRP3 inflammasome and related risk factors for T2D compared to subjects with higher PCSK9 and lower WAT LDLR and CD36 despite lack of group differences in body composition, basal metabolic rate, and energy and macronutrient intake.